Pharma Business - April 11, 2023
AstraZeneca’s Ultomiris recommended for approval in the EU
Ultomiris has been recommended for marketing authorization in the European Union for the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive. If authorised, Ultomiris would be the first and only approved long-acting C5 complement inhibitor for the treatment of AQP4 Ab+ NMOSD in the EU, states the company. “For […]
Biotech Business - April 5, 2023
Alligator announces authorization to initiate Phase 2 trial
Alligator Bioscience has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the company to initiate the OPTIMIZE-2 Phase 2 trial evaluating its lead asset mitazalimab in urothelial carcinoma. This open-label, multi-center study aims to assess the safety and efficacy of an immunotherapeutic combination of […]
Biotech Business - April 4, 2023
Modus has secured access to bridge financing of up to 7 MSEK
Modus Therapeutics secures access to bridge financing from longstanding investor Karolinska Development. Access to this funding ensures that momentum of clinical development of Modus’ lead asset, sevuparin, will be enhanced while the company continues to explore licensing and partnership opportunities, it states. These future development plans include preparation for a Phase 2a study evaluating sevuparin […]
Biotech Business - April 3, 2023
Oncopeptides receives a research grant from Vinnova
Oncopeptides has received a research grant of 3 million SEK from Sweden’s Innovation Agency (Vinnova), to explore the development of new treatment options for glioblastoma, an aggressive and incurable form of brain cancer. The grant enables exploratory research to better understand the potential of the PDC platform in solid tumors such as glioblastoma. “We are […]
Financing - March 30, 2023
Vakona receives 14 million SEK investment
Vakona has been given a capital injection from five investors to help it develop a new drug to treat acne. “This is a significant investment for us, as now we can continue with our product development,” says Gabriella Persson, CEO of Vakona. Three of the investors, Stoaf III SciTech, Partnerinvest Norr and Phase2Phase Biopharma, have […]
Acquisition - March 29, 2023
Navamedic submits offer to acquire Sensidose
The Norwegian company has submitted a cash offer to acquire all shares in Swedish Sensidose for approximately 75 million SEK. The offer is recommended by the independent bid committee of Sensidose. The Sensidose shares are currently listed on Spotlight Stock Market in Sweden. “This potential transaction is an excellent example of Navamedic’s proactive approach to […]
